the aid library

LIST OPTIONS

Filter

5461

Sort by:

Direction:

Download (439)

View PDF (795)

Antimicrobial Stewardship Program Guideline (India)
recommended

Balaji, V., P. Rupali, K. Walia, et al. Indian Council of Medical Research (2018) C2

Antimicrobial resistance (AMR) is a major public health challenge, which is recognized as high priority area by the Government of India. The increasing consumption of antibiotics is one of the key drivers of antimicrobial resistance seen in bugs of public health importance. Irrational prescription o... more

Download (186)

View PDF (448)

Ethiopia: Antimicrobial Resistance Prevention and Containment Strategic Plan: The One Health Approach 2021-2025

Ethiopian Food, Medicine and Healthcare Administration and Control Authority (2021) C2

To understand the national situation, Ethiopia did a situation assessment, launched its first strategy in 2011, and took action to contain AMR, as detailed in the blue boxes found throughout this strategy. This updated version of the strategy was in response to the revised health and medicines polic... more

Download (208)

View PDF (265)

Person-centred recovery planning for mental health and well-being: self-help tool: WHO QualityRights

World Health Organization WHO (2019) C_WHO

Ensuring mental health and well-being has become a worldwide imperative and an important target of the Sustainable Development Goals. But in all countries around the world, our response has been woefully insufficient, and we have made little progress to advance mental health as a fundamental human ... more

Download (135)

View PDF (202)

Всесвітня організація охорони здоров’я. Інструмент самодопомоги з планування людиноорієнтованого процесу відновлення психічного здоров’я та благополуччя. Ініціатива ВООЗ QualityRights

World Health Organization WHO (2022) C_WHO

Навчальні та методичні модулі ініціативи ВООЗ QualityRights було розроблено з метою покращення знань, навичок та розуміння ключових зацікавлених сторін про те, як сприя�... more

Download (86)

View PDF (141)

Kherson Rapid Assessment: Civilian protection needs & responses (November 2022)

Nonviolent Peaceforce (2022) C2

On November 9, the Russian military announced a full retreat of all their forces from the right bank of Dnipro River; by November 11, 41 settlements, including Kherson city, were de-occupied by Ukrainian forces. Civilians who live in these areas have endured months of combat and occupation. Services... more

Download (132)

View PDF (146)

Traditions and Opportunities - A Toolkit for GBV Programs to Engage Community Leaders in Humanitarian Settings [EN/AR]

International Medical Corps (IMC) (2021) C2

Travailler avec les dirigeants communautaires pour lutter contre la VBG est une très bonne et prometteuse approche, car les dirigeants communautaires sont les gardiens de toutes nos croyances et coutumes. Étant donné que la VBG est enracinée dans les croyances et les coutumes, essayer de s�... more

Download (69)

View PDF (536)

“Female genital schistosomiasis is a sexually transmitted disease”: Gaps in healthcare workers’ knowledge about female genital schistosomiasis in Tanzania

Mazigo, H.; Samson, A.; Lambert, V. et al. PLoS Global Public Health (2022) CC

Female Genital Schistosomiasis (FGS) is a gynaecological disease caused by Schistosoma haematobium, a parasitic worm that is acquired by skin contact with freshwater contaminated by schistosome cerceriae. Communities in which the infection is most endemic have limited access to clean water and healt... more

Download (81)

View PDF (611)

Ethiopia - National Cholera Control Operational Plan 2022/23

Government of Ethiopia (2023) CC

Cholera is a diarrheal disease caused by the bacterium Vibrio cholera. The infection primarily spreads through contaminated water and food. Symptoms include the onset of acute diarrhea and/or vomiting, muscle cramps, and body weakness. If untreated, the infection can result in rapid dehydration and ... more

Download (168)

View PDF (208)

Preventing and responding to sexual misconduct WHO’s three-year strategy 2023-2025

World Health Organisation (WHO) (2023) C_WHO

Sexual exploitation, sexual abuse and sexual harassment (SEAH) violate the rights and wellbeing of the people we serve and the people with whom we serve. Such behaviours are directly in opposition to WHO’s values and our abiding responsibility to do no harm. WHO uses the umbrella term “sexual mi... more

Download (94)

View PDF (438)

Diagnostics to support the eradication of yaws—Development of two target product profiles

Fongwen, N.; Handley, B.; Martin, D. et al. PLoS Neglected Tropical diseases (2022) CC

Yaws is targeted for eradication by 2030, using a strategy based on mass drug administration (MDA) with azithromycin. New diagnostics are needed to aid eradication. Serology is currently the mainstay for yaws diagnosis; however, inaccuracies associated with current serological tests makes it difficu... more

Download (119)

View PDF (678)

Towards a Human Rights-Based Approach to Migration: Training Guide

UN Office of the High Commissioner for Human Rights OHCHR (20023) CC

This training guide is designed to enable participants to understand the human rights perspective on migration, and how human rights laws and standards can be operationalized to make migration safer and an empowering experience for all. It provides an introduction to related principles and issues an... more

Download (176)

View PDF (521)

National Guidelines for Diabetic Eye Care

Ministry of Health Malawi (2021) CC

Diabetes mellitus (DM) is a global epidemic with significant morbidity. Diabetic retinopathy (DR) is the specific microvascular complication of DM and affects 1 in 3 persons with DM. DR remains a leading cause of vision loss in working adult populations. Patients with severe levels of DR are report... more

Download (80)

View PDF (314)

Report of a global meeting on yaws eradication surveillance, monitoring and evaluation: Geneva, 29–30 January 2018

World Health Organization WHO; Institutional research information sharing iris (2018) C_WHO

Report of a global meeting on yaws eradication surveillance, monitoring and evaluation: Geneva, 29–30 January 2018. World Health Organization.

Download (171)

View PDF (164)

Forests and Trees for Human Health: Pathways, Impacts, Challenges and Response Options

Cecil Konijnendijk, Dikshya Devkota, Stephanie Mansourian & Christoph Wildburger (eds.) International Union of Forest Research Organizations (IUFRO) (2023) C2

Forests, trees and green spaces, hereinafter ‘forests and trees’ for short, provide multiple goods and services that contribute to human health. These include medicines, nutritious foods and other non-wood forest products (NWFPs). Globally, at least 3.5 billion people use NWFPs, including medici... more

Download (86)

View PDF (327)

Africa CDC Event-based Surveillance Resources

Africa Center for Disease Control and Prevention (2023) CC

The Event-based Surveillance Framework is intended to be used by authorities and agencies responsible for surveillance and response. This framework serves as an outline to guide stakeholders interested in implementing event-based surveillance (EBS) using a multisectoral, One Health approach. To ... more

Download (129)

View PDF (165)

Keeping the vector out: housing improvements for vector control and sustainable development

Kraef, C.; Röbbel, N. World Health Organization WHO (2017) C_WHO

Vector-borne diseases are responsible for 17% of the global burden of communicable diseases and more than 500 000 deaths annually. The ambitious global targets for the control of vector-borne diseases come in the context of the (re-)emergence of diseases, increasing resistances to insecticides and u... more

Download (204)

View PDF (168)

Global oral health status report: towards universal health coverage for oral health by 2030: regional summary of the Western Pacific Region

World Health Organisation (WHO) (2023) C_WHO

This regional summary draws on the WHO Global oral health status report (2), published in 2022, which provides a comprehensive overview of the global oral disease burden, the global health importance of oral health and the impact of oral diseases over the life course. The summary focuses on the ... more

Download (184)

View PDF (169)

The state of food security and nutrition in the world 2023

World Health Organisation (WHO) (2023) C_WHO

This report is the annual global monitoring report documenting progress towards Sustainable Development Goal (SDG) 2 targets 2.1 and 2.2. This year’s report explores the links between urbanization and changing food systems and how these changes are impacting the availability, affordability and des... more

Download (140)

View PDF (115)

Communicating about Vaccination-related Risks

World Health Organisation (WHO) (2023) C_WHO

This document seeks to help health communication professionals working on the topic of immunization more effectively communicate about Events Supposedly Attributed to Vaccination and Immunization (ESAVI) by building trust in National Immunization Programs, understanding risk perceptions related to v... more

Download (245)

View PDF (329)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Antimicrobial Stewardship Program Guideline (India) recommended

Antimicrobial Stewardship Program Guideline (India)
recommended